The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
An online stress management program may significantly improve the quality of life for patients newly diagnosed with cancer, according to a recent study.
A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
A recent study found a link between HbA1C levels, diabetes status, and long-term cognitive decline.
The National Comprehensive Cancer Network has updated their guideline for breast cancer risk reduction, including significant changes to the section on components of risk/benefit assessment and counseling.
Focal therapy for primary localized prostate cancer should remain investigational pending further study, according to a 2018 European Association of Urology position paper.
Brian Bastean, PharmD, MBA, has identified some of the most important and influential research in recent months contributing to value-based care, health economics and outcomes research, and clinical pathways.
What is the most concerning issue in clinical pathways today?